Matthew Colonnese, PhD, Seeks to Improve Diagnostic Utility of Neonatal EEGs

Researchers at the George Washington University (GW) are laying the groundwork for a future in which health care providers can more accurately diagnose brain injury and dysfunction in newborns with the use of an inexpensive and non-invasive diagnostic tool — electroencephalography (EEG).

Fetus

The research, led by Matthew Colonnese, PhD, associate professor of pharmacology and physiology at the GW School of Medicine and Health Sciences, was recently funded with more than $4 million in grants from the National Eye Institute and the National Institute of Neurological Disorders and Stroke.

The researchers seek to expand current knowledge of how changes in brain connections to the cerebral cortex control the normal development of brain activity that occurs around the time of birth.

Despite more than 65 years of EEG use on newborns, understanding of rhythmic cortical activity patterns associated with brain development and injury is limited. The funding will enable the research team to help improve the interpretation and understanding of the EEG in babies, both preterm and full term.

Latest News

The George Washington University (GW) Medical Faculty Associates (MFA) is extending its reach in suburban communities, expanding primary care services and bringing convenient, high-quality, and comprehensive health care to Northern Virginia, suburban Maryland, and the Washington, D.C., metropolitan…
Medicine is slowly evolving into a multimedia arena, one that melds in-person visits with technology-based care. This shift has been convenient and cost-effective for both patients and doctors, but it also has opened an avenue to care for a specific patient population: the elderly.
The George Washington University School of Medicine and Health Sciences, under the leadership of Maranda C. Ward, EdD ’17, has been awarded a pair of grants totaling more than $816,000 from Gilead Sciences Inc., in support of an 18-month research-informed educational initiative, Two in One: HIV+…